Differing risk of cancer death among patients with lymph node metastasis after radical prostatectomy and pelvic lymph node dissection: Identification of risk categories according to number of positive nodes and Gleason score

BJU International

Volumn 111, Issue 8, 2013, Pages 1237-1244

  Schiavina, Riccardo ^a   Borghesi, Marco ^a   Brunocilla, Eugenio ^a   Manferrari, Fabio ^a   Fiorentino, Michelangelo ^a,b   Vagnoni, Valerio ^a   Baccos, Alessandro ^a   Pultrone, Cristian Vincenzo ^a   Rocca, Giovanni Christian ^a   Rizzi, Simona ^a   Martorana, Giuseppe ^a  

^a UNIVERSITY OF BOLOGNA   (Italy)

^b HARVARD UNIVERSITY   (United States)

Author keywords

Gleason score; lymph node metastasis; pelvic lymph node dissection; radical prostatectomy; survival

Indexed keywords

ADULT; AGED; ARTICLE; CANCER MORTALITY; CANCER SPECIFIC SURVIVAL; FOLLOW UP; GLEASON SCORE; HUMAN; KAPLAN MEIER METHOD; LYMPH NODE DISSECTION; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PELVIS LYMPH NODE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; PROSTATE CANCER; PROSTATECTOMY; SURVIVAL RATE;

AGED; FOLLOW-UP STUDIES; HUMANS; ITALY; LYMPH NODE EXCISION; LYMPH NODES; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM GRADING; PELVIS; PROGNOSIS; PROSTATECTOMY; PROSTATIC NEOPLASMS; RETROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; SURVIVAL RATE; TIME FACTORS;

EID: 84878338029     PISSN: 14644096     EISSN: 1464410X     Source Type: Journal    
DOI: 10.1111/j.1464-410X.2012.11602.x     Document Type: Article

References (31)

1. Cheng L, Zincke H, Blute ML, Bergstrach EJ, Scherer B, Bostwick OG,. Risk of prostate carcinoma death in patients with lymph node metastasis. Cancer 2001; 91: 66-73 (Pubitemid 32052615)
2. Boorjian SA, Thompson RH, Siddiqui S, et al. Long-term outcome after radical prostatectomy for patients with lymph node positive prostate cancer in the prostate specific antigen era. J Urol 2007; 178: 864-871 (Pubitemid 47211081)
3. Daneshmand S, Quek ML, Stein JP, et al. Prognosis of patients with lymph node positive prostate cancer following radical prostatectomy: long-term results. J Urol 2004; 172: 2252-2255 (Pubitemid 39507502)
4. Palapattu GS, Allaf ME, Trock BJ, Epstein JI, Walsh PC,. Prostate specific antigen progression in men with lymph node metastases following radical prostatectomy: results of long-term follow-up. J Urol 2004; 172: 1860-1864 (Pubitemid 39363074)
5. vonBodman C, Godoy G, Chade DC, et al. Predicting biochemical recurrence-free survival for patients with positive pelvic lymph nodes at radical prostatectomy. J Urol 2010; 184: 143-148
6. Schumacher MC, Burkhard FC, Thalmann GN, Fleischmann A, Studer UE,. Good outcome for patients with few lymph node metastases after radical retropubic prostatectomy. Eur Urol 2008; 54: 344-352
7. Masterson TA, Bianco FJ Jr, Vickers AJ, et al. The association between total and positive lymph nodes counts, and disease progres- sion in clinically localized prostate cancer. J Urol 2006; 175: 1320-1324
8. Zwergel U, Lehmann J, Wullich B, Schreier U, Remberger K, Zwergel T, Stoeckle M,. Lymph node positive prostate cancer: long-term survival data after radical prostatectomy. J Urol 2004; 171: 1128-1131 (Pubitemid 38327541)
9. Bader P, Burkhard FC, Markwalder R, Studer UE,. Disease progression and survival of patients with positive lymph nodes after radical prostatectomy. Is there a chance for cure? J Urol 2003; 169: 849-854 (Pubitemid 36188105)
10. Grimm MO, Kamphausen S, Hugenschmidt H, Stephen-Odenthal M, Ackermann R, Vögeli TA,. Clinical outcome of patients with lymph node positive prostate cancer after radical prostatectomy versus androgen deprivation. Eur Urol 2002; 41: 628-634 (Pubitemid 35333920)
11. Siddiqui SA, Boorjian SA, Inman B, Bagniewski S, Bergstralh EJ, Blute ML,. Timing of androgen deprivation therapy and its impact on survival after radical prostatectomy: a matched cohort study. J Urol 2008; 179: 1830-1837
12. Frohmüller HG, Theiss M, Manseck A, Worth MP,. Survival and quality of life of patients with stage D1 (T1-3 pN1-2 M0) prostate cancer. Radical prostatectomy plus androgen deprivation versus androgen deprivation alone. Eur Urol 1995; 27: 202-206
13. Cadeddu JA, Partin AW, Epstein JI, Walsh PC,. Stage D1 (T1-3, N1-3, M0) prostate cancer: a case-controlled comparison of conservative treatment versus radical prostatectomy. Urology 1997; 50: 251-255 (Pubitemid 27339942)
14. Cheng L, Bergstralh EJ, Cheville JC, et al. Cancer volume of lymph node metastasis predicts progression in prostate cancer. Am J Surg Pathol 1998; 22: 1491-1500 (Pubitemid 28550644)
15. Fleischmann A, Schobinger S, Markwalder R, Schumacher M, Burkhard F, Thalmann GN, Studer UE,. Prognostic factors in lymph node metastases of prostatic cancer patients: the size of the metastases but not extranodal extension independently predicts survival. Histopathology 2008; 53: 468-475
16. Fleischmann A, Schobinger S, Schumacher M, Thalman GN, Studer UE,. Survival in surgically treated, nodal positive prostate cancer patients is predicted by histopathological characteristics of the primary tumor and its lymph node metastases. Prostate 2009; 69: 352-362
17. Schmid H-P, Mihatsch MJ, Hering F, Rutishauser G,. Impact of minimal lymph node metastasis on long-term prognosis after radical prostatectomy. Eur Urol 1997; 31: 11-16 (Pubitemid 27058097)
18. Cheng L, Pisansky TM, Ramnani DM, et al. Extranodal extension in lymph node-positive prostate cancer. Mod Pathol 2000; 13: 113-118 (Pubitemid 30109096)
19. Griebling TL, Ozkutlu D, See WA, Cohen MB,. Prognostic implications of extracapsular extension of lymph node metastases in prostate cancer. Mod Pathol 1997; 10: 804-809 (Pubitemid 27374851)
20. Cheng L, Montironi R, Bostwick DG, Lopez-Beltran A, Berney DM,. Staging of prostate cancer. Histopathology 2012; 60: 87-117
21. Hofer MD, Kuefer R, Huang W, et al. Prognostic factors in lymph node-positive prostate cancer. Urology 2006; 67: 1016-1021 (Pubitemid 43956399)
22. Schiavina R, Scattoni V, Castellucci P, et al. 11C-Choline positron emission tomography/computerized tomography for preoperative lymph-node staging in intermediate-risk and high-risk prostate cancer: comparison with clinical staging nomograms. Eur Urol 2008; 54: 392-401
23. Cagiannos I, Karakiewicz P, Eastham JA, et al. A preoperative nomogram identifying decreased risk of positive pelvic lymph nodes in patients with prostate cancer. J Urol 2003; 170: 1798-1803 (Pubitemid 37254931)
24. Briganti A, Chun FK, Salonia A, et al. Validation of a nomogram predicting the probability of lymph node invasion based on the extent of pelvic lymphadenectomy in patients with clinically localized prostate cancer. BJU Int 2006; 98: 788-793 (Pubitemid 44368026)
25. Greene FL, Page DL, Fleming ID, et al. American Joint Committee on Cancer Staging Manual, 6th edn. Philadelphia: Springer, 2002
26. Heidenreich A, Aus G, Bolla M, Jonian S, Marveen VB, Schmid HP, Zarroni F,. EAU guidelines on prostate cancer. Eur Urol 2008; 53: 68-80 (Pubitemid 350166735)
27. Dorin RP, Lieskovsky G, Fairey AS, Cai J, Daneshmand S,. Outcomes after radical prostatectomy for patients with clinical stages T1-T2 prostate cancer with pathologically positive lymph nodes in the prostate-specific antigen era. Urol Oncol 2012; doi: http://dx.doi.org/10.1016/j.uroonc.2012.03.006 (in press)
28. Schiavina R, Bertaccini A, Franceschelli A, et al. The impact of the extent of lymph-node dissection on biochemical relapse after radical prostatectomy in node-negative patients. Anticancer Res 2010; 30: 2297-2302
29. Schiavina R, Manferrari F, Garofalo M, et al. The extent of pelvic lymph node dissection correlates with the biochemical recurrence rate in patients with intermediate- and high-risk prostate cancer. BJU Int 2011; 108: 1262-1268
30. Martorana G, Schiavina R, Franceschelli A,. Should we perform imaging-guided lymph node dissection in patients with lymphatic recurrence of prostate cancer after radical prostatectomy? Eur Urol 2009; 55: 1302-1304
31. Briganti A, Karnes JR, Da Pozzo LF, et al. Two positive nodes represent a significant cut-off value for cancer specific survival in patients with node positive prostate cancer. A new proposal based on a two-institution experience on 703 consecutive N + patients treated with radical prostatectomy, extended pelvic lymph node dissection and adjuvant therapy. Eur Urol 2009; 55: 261-270